The variant of covid-19 identified in South Africa may compromise the effectiveness of at least two vaccines. This is the conclusion of a published study, which says that this mutation affects the performance of products developed by the pharmaceutical companies Novavax and Johnson & Johnson, which this Friday announced the first results after the phase 3 tests.
The study cited by the agency Reuters says that the preventive capacity of the disease can be affected after tests have been done on participants in South Africa.
The director of the National Institute of Allergology and Infectious Diseases of the United States has already admitted that these new variants (in addition to the South African, mutations have been detected in Brazil and the United Kingdom).
We realize that this is a challenge for us “, afirmou Anthony Fauci.
A Novavax announced 90% effectiveness against covid-19, assuming that this effectiveness could be compromised to 50% in the case of the South African variant.
Me and Johnson & Johnson announced an overall effectiveness of 66%. This effectiveness was, however, very different depending on the region. If in the United States the results were 72%, in South Africa the same figure dropped to 57%, corroborating the conclusions of the study presented.
This discovery raises questions about the vaccines that are already being administered, namely those of Pfizer and Moderna, which are already in use in Portugal, but also that of AstraZeneca, which should arrive in our country in a few days.